Search

The G2 object has recently passed its pericenter passage in our Galactic Center. While the $Br_\gamma$ emission shows clear signs of tidal interaction, the change in the observed luminosity is only of about a factor of 2, in contention with all previous predictions. We present high resolution simulations performed with the moving mesh code, RICH, together with simple analytical arguments that reproduce the observed $Br_\gamma$ emission. In our model, G2 is a gas cloud that undergoes tidal disruption in a dilute ambient medium. We find that during pericenter passage, the efficient cooling of the cloud results in a vertical collapse, compressing the cloud by a factor of $\sim5000$. By properly taking into account the ionization state of the gas, we find that the cloud is UV starved and are able to reproduce the observed $Br_\gamma$ luminosity. For densities larger than $\approx500\;\mathrm{cm}^{-3}$ at pericenter, the cloud fragments, due to cooling instabilities and the emitted radiation is inconsistent with observations. For lower densities, the cloud survives the pericenter passage intact and its emitted radiation matches the observed lightcurve. From the duration of $Br_\gamma$ emission which contains both redshifted and blueshifted components, we show that the cloud is not spherical but rather elongated with a size ratio of 4 at year 2001. The simulated cloud's elongation grows as it travels towards pericenter and is consistent with observations, due to viewing angles. The simulation is also consistent with having a spherical shape at apocenter.

BACKGROUND The aim of this study was to evaluate the long-term prognosis of children with hemolytic uremic syndrome (HUS). METHODS Over a 6-year period, 619 pediatric patients with the clinical diagnosis of HUS were registered in Austria and Germany, and a subset (n = 274) was prospectively followed up for 5 years. RESULTS Infection with enterohemorrhagic Escherichia coli (EHEC) was confirmed in 79% of cases. Five years after diagnosis, 70% of EHEC-infected patients (95% confidence interval [CI], .63-.76) were fully recovered. The remaining 30% had persistent hypertension (9%), neurological symptoms (4%), decreased glomerular filtration rate (7%), and/or proteinuria (18%). Hypertension and proteinuria developed in a total of 18% of patients who had no sequelae 1 year after the acute phase (95% CI, 12-26). Multivariate logistic regression analysis demonstrated an association between the use of plasma therapy during acute phase and poor long-term outcome (odds ratio, 2.9-13; 95% CI, 2.4-33; P < .05), but this treatment was also used more frequently in severe cases. In contrast, the use of antibiotic therapy in the diarrheal phase and other established risk factors for developing HUS, such as Shiga toxin 2 and EHEC serotypes traditionally considered to be "high risk," were not associated with adverse long-term outcome. In particular, there was no difference between O157 and non-O157 EHEC. CONCLUSIONS This study identified an association between the use of plasma treatment and poor long-term outcome and confirms already known risk factors for poor prognosis. Follow-up investigations for at least 5 years are recommended to detect late-emerging sequelae.